? MEDICINAL CHEMISTRY SHARED RESOURCE (MCSR) The MCSR supports scientific endeavors of OSUCCC members to create chemical probes to disrupt molecular pathways implicated in tumor growth, and to work with investigators to identify and create targeted agents against novel therapeutic moieties selected for properties important for preclinical and clinical development. The MCSR was established as a developing shared resource in 2011, and became a full CCSG shared resource in 2015. The MCSR supports investigators conducting preclinical in vitro and in vivo studies by integrating the expertise of multiple disciplines, including medicinal chemistry, process chemistry, computational chemistry, structural biology and molecular pharmacology. Key services are custom synthesis and lead optimization, including structure activity relationship analysis and structure-based optimization. Overall, the MCSR provides a crucial niche service for investigators identifying new therapeutic compounds.
The Specific Aims of the MCSR are: 1) enable researchers to develop chemical probes of cancer biology; 2) Optimize hit and lead molecules through the design and synthesis of analogs with improved drug-like properties for translational development as cancer therapeutics; and 3) as a developing aim, enable screening of small molecules against proteins and whole-cell assays to identify new compounds for further preclinical testing. For this Developing Aim, Dr. Blake Peterson (TT) has been added as co-Director of the MCSR, and the OSUCCC will invest $3M in small molecule screening; these new capabilities will require hiring additional staff and a technical director, purchasing of equipment to conduct screens, and renovation of space. Over the current grant cycle, the MCSR supported 34 investigators (79% OSUCCC members) from all five research programs, including members at Nationwide Children's Hospital, and provided 7,625 hours of service (81.7% to OSUCCC members). The MCSR also contributed to 29 publications (9 > 10 impact factor), 34 users, and 7 NCI grants, including 1 K12, 1 U01, 1 R35, 1 R01, 2 P01s, and 1 P50. Over the next grant cycle, the MCSR will directly support the OSUCCC's strategic priorities for immuno-oncology and translational genomics. It will also support the development of drugs with potential for cancer prevention. The major thrust for the MCSR will be to implement small molecule screening and build the user base to identify novel compounds, and targets by phenotypic screening against cancer pathways, thereby identifying mechanisms of cancer initiation and progression that are central to goals of CB and MCC. The annual budget of the MCSR is $930,296, yet the CCSG request is $80,063. As such, the MCSR seeks only 8.6% budgetary support from CCSG funds.
|LaPak, Kyle M; Vroom, Dennis C; Garg, Ayush A et al. (2018) Melanoma-associated mutants within the serine-rich domain of PAK5 direct kinase activity to mitogenic pathways. Oncotarget 9:25386-25401|
|Byrd, John C; Smith, Stephen; Wagner-Johnston, Nina et al. (2018) First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget 9:13023-13035|
|Kaffenberger, Benjamin H; Hinton, Alice; Krishna, Somashekar G (2018) The impact of underlying disease state on outcomes in patients with pyoderma gangrenosum: A national survey. J Am Acad Dermatol 79:659-663.e2|
|Horowitz, Neil S; Larry Maxwell, G; Miller, Austin et al. (2018) Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study. Gynecol Oncol 148:49-55|
|Rahnemai-Azar, Amir A; Cloyd, Jordan M; Weber, Sharon M et al. (2018) Update on Liver Failure Following Hepatic Resection: Strategies for Prediction and Avoidance of Post-operative Liver Insufficiency. J Clin Transl Hepatol 6:97-104|
|Rebbeck, Timothy R (see original citation for additional authors) (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620|
|Kodigepalli, Karthik M; Bonifati, Serena; Tirumuru, Nagaraja et al. (2018) SAMHD1 modulates in vitro proliferation of acute myeloid leukemia-derived THP-1 cells through the PI3K-Akt-p27 axis. Cell Cycle 17:1124-1137|
|Zhang, Tianyu; Xu, Jielin; Deng, Siyuan et al. (2018) Core signaling pathways in ovarian cancer stem cell revealed by integrative analysis of multi-marker genomics data. PLoS One 13:e0196351|
|Yang, Zhifen; Zhang, Jing; Jiang, Dadi et al. (2018) A Human Genome-Wide RNAi Screen Reveals Diverse Modulators that Mediate IRE1?-XBP1 Activation. Mol Cancer Res 16:745-753|
|Toland, Amanda Ewart; Forman, Andrea; Couch, Fergus J et al. (2018) Clinical testing of BRCA1 and BRCA2: a worldwide snapshot of technological practices. NPJ Genom Med 3:7|
Showing the most recent 10 out of 2602 publications